<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Fani Maleki A</submitter><funding>CIHR</funding><pagination>218</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7376735</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>17(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Muramyl dipeptide (MDP) is a component derived from minimal peptidoglycan motif from bacteria, and it is a ligand for the NOD2 receptor. Peripheral administration of MDP converts Ly6C&lt;sup>high&lt;/sup> into Ly6C&lt;sup>low&lt;/sup> monocytes. Previously, we have shown that Ly6C&lt;sup>low&lt;/sup> monocytes play crucial roles in the pathology of a mouse model of Alzheimer's disease (AD). However, medications with mild immunomodulatory effects that solely target specific monocyte subsets, without triggering microglial activation, are rare.&lt;h4>Methods&lt;/h4>Three months old APP&lt;sub>swe&lt;/sub>/PS1 transgenic male mice and age-matched C57BL/6 J mice were used for high frequency (2 times/week) over 6 months and low frequency (once a week) over 3 months of intraperitoneally MDP (10 mg/kg) admin</pubmed_abstract><journal>Journal of neuroinflammation</journal><pubmed_title>Muramyl dipeptide-mediated immunomodulation on monocyte subsets exerts therapeutic effects in a mouse model of Alzheimer's disease.</pubmed_title><pmcid>PMC7376735</pmcid><funding_grant_id>331652</funding_grant_id><pubmed_authors>Laflamme N</pubmed_authors><pubmed_authors>Plante MM</pubmed_authors><pubmed_authors>Gosselin J</pubmed_authors><pubmed_authors>Rivest S</pubmed_authors><pubmed_authors>Cisbani G</pubmed_authors><pubmed_authors>Prefontaine P</pubmed_authors><pubmed_authors>Fani Maleki A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Muramyl dipeptide-mediated immunomodulation on monocyte subsets exerts therapeutic effects in a mouse model of Alzheimer's disease.</name><description>&lt;h4>Background&lt;/h4>Muramyl dipeptide (MDP) is a component derived from minimal peptidoglycan motif from bacteria, and it is a ligand for the NOD2 receptor. Peripheral administration of MDP converts Ly6C&lt;sup>high&lt;/sup> into Ly6C&lt;sup>low&lt;/sup> monocytes. Previously, we have shown that Ly6C&lt;sup>low&lt;/sup> monocytes play crucial roles in the pathology of a mouse model of Alzheimer's disease (AD). However, medications with mild immunomodulatory effects that solely target specific monocyte subsets, without triggering microglial activation, are rare.&lt;h4>Methods&lt;/h4>Three months old APP&lt;sub>swe&lt;/sub>/PS1 transgenic male mice and age-matched C57BL/6 J mice were used for high frequency (2 times/week) over 6 months and low frequency (once a week) over 3 months of intraperitoneally MDP (10 mg/kg) admin</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Jul</publication><modification>2025-04-04T22:32:33.722Z</modification><creation>2025-04-04T22:32:33.722Z</creation></dates><accession>S-EPMC7376735</accession><cross_references><pubmed>32698829</pubmed><doi>10.1186/s12974-020-01893-3</doi></cross_references></HashMap>